Literature DB >> 9550628

Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996).

R E Schmieder1, M P Schlaich, A U Klingbeil, P Martus.   

Abstract

OBJECTIVE: To provide an update on the ability of different antihypertensive drugs to reduce left ventricular hypertrophy in essential hypertension. DATA SOURCES: Relevant medical databases including MEDLINE, BIOSIS PREVIEWS, EMBASE, and SCISEARCH as well as review articles to December 1996. STUDY SELECTION: Meta-analysis of all published articles including only double-blind, randomized, controlled clinical studies with parallel-group design. DATA EXTRACTION: Literature search and data extraction according to a prefixed scheme performed independently by two investigators. The primary parameter was reduction of left ventricular mass by antihypertensive therapy with placebo, diuretics, beta-blockers, calcium channel blockers, or ACE-inhibitors. DATA SYNTHESIS: Fifty studies published till the end of December 1996 were identified. They comprised a total of 1715 patients in 13 placebo (n=165, age: 50+/-3 years) and 89 active treatment arms (n=1550, age: 56+/-10 years) respectively. Overall, for active treatment left ventricular mass index was the more reduced the greater the decrease in systolic blood pressure, (r=0.27; P<0.05), the longer the duration of therapy (r=0.36; P<0.001), and the higher the pretreatment value of left ventricular mass index (r= 0.53; P<0.001). Left ventricular mass index was decreased by 12% with ACE-inhibitors (95% CI: 9.0-14.5%), by 11% with calcium channel blockers (95% CI: 7.8-13.7%), by 5% with beta-blockers (95% CI: 1.2-7.3%) and by 8% with diuretics (95% CI: 3.9-11.1%) (overall P<0.01). Subsequent tests revealed that ACE-inhibitors and calcium channel blockers were more effective than beta-blockers in reducing left ventricular mass index (P<0.05). Similar differences between drug classes were found with regard to effect on left ventricular wall thickness (P<0.05).
CONCLUSIONS: Decrease in systolic blood pressure, duration of antihypertensive therapy, degree of pretreatment left ventricular hypertrophy and antihypertensive drug class determined the reduction of left ventricular hypertrophy. ACE-inhibitors and calcium channel blockers were more potent in reducing left ventricular mass than beta-blockers, with diuretics in the intermediate range.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9550628     DOI: 10.1093/ndt/13.3.564

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  27 in total

Review 1.  Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.

Authors:  Risto S Cvetković; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Regression of left ventricular hypertrophy in children with antihypertensive therapy.

Authors:  Prema Ramaswamy; Irene D Lytrivi; Chikku Paul; Mary Golden; Juan C Kupferman
Journal:  Pediatr Nephrol       Date:  2006-09-06       Impact factor: 3.714

Review 3.  Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update.

Authors:  Alberto Milan; Mimma A Caserta; Eleonora Avenatti; Sara Abram; Franco Veglio
Journal:  Intern Emerg Med       Date:  2010-05-18       Impact factor: 3.397

Review 4.  The ACE gene and human performance: 12 years on.

Authors:  Zudin Puthucheary; James R A Skipworth; Jai Rawal; Mike Loosemore; Ken Van Someren; Hugh E Montgomery
Journal:  Sports Med       Date:  2011-06-01       Impact factor: 11.136

Review 5.  End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function.

Authors:  Giuliano Tocci; Massimo Volpe
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

6.  Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy.

Authors:  Wolfgang Lieb; Jochen Graf; Anika Götz; Inke R König; Björn Mayer; Marcus Fischer; Jan Stritzke; Christian Hengstenberg; Stephan R Holmer; Angela Döring; Hannelore Löwel; Heribert Schunkert; Jeanette Erdmann
Journal:  J Mol Med (Berl)       Date:  2005-11-11       Impact factor: 4.599

Review 7.  Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 3: Angiotensin-converting-enzyme inhibitors.

Authors:  J M Wright
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

Review 8.  [Hypertension and cardiac failure].

Authors:  C M Schannwell; M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2007-09       Impact factor: 0.743

Review 9.  Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension.

Authors:  M Asif A Siddiqui; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.

Authors:  Alain J Nordmann; Murray Krahn; Alexander G Logan; Gary Naglie; Allan S Detsky
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.